




# Life Sciences Financing Summary Europe

August 2015

After a promising start in April, the second quarter of 2015 has closed with only two rounds of financing for private European Biotech companies (Therapeutics & Diagnostics) one each in May and June. Going public in the sector was only attempted by French vaccines and anti-virals ABIVAX, that launched its initial public offering in June, raising EUR 58.2m.

The two private financing rounds for European Therapeutics & Diagnostics companies were collected by the British PsiOxus in May and Auspherix in June 2015. Continue reading below to learn more about the financing highlights of May and June 2015 in the European Life Science industry.

Europe - Biotech Therapeutic Financing Rounds



Source: Biotechgate.com

\*The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.

## Selected financing highlights: companies raising funds

### June 2015

#### **Auspherix Raises GBP 6m (EUR 8.3m) and Establishes UK Operations**

Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, raised, GBP 6m (EUR 8.3m) on the 3th of June 2015, in a Series A venture financing, and is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK. New investor Imperial Innovations plc (AIM IVO) led the round alongside Australian founding investor the Medical Research Commercialisation Fund (MRCF).

The investment will be used to fund the company's drug discovery programme, expand the management team and recruit a microbiology team. Auspherix aims to progress its novel class of antibacterials, which have a novel mechanism of action, through lead optimization to final candidate selection within the next two years. Auspherix's current lead compounds show activity against a broad range of multidrug resistant (MDR) Gram-negative and Gram-positive bacterial infections.

The company anticipates appointing a CEO within the coming months, and is building out its Stevenage-based R&D team. (Source: press release)

### May 2015

#### **PsiOxus therapeutics raises a GBP 25m (EUR 34.6m) Series C investment**

Oxford (UK)-based PsiOxus Therapeutics Ltd. (PsiOxus) closed, on the 19<sup>th</sup> of May 2015, a Series C financing round of GBP 25m (EUR 34.6m) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the antibody 'armed' series of AbEnAd viruses.

Founding investor Imperial Innovations led the Series C round alongside other current investors: Invesco, SROne (investment arm of GlaxoSmithKline), Lundbeckfond Ventures and Mercia Technologies. In addition, one new investor, Woodford Investment Management, has joined the syndicate via the recently formed Woodford Patient Capital Trust.

PsiOxus' lead product, enadenotucirev, is an oncolytic virus that has been shown in Phase I clinical trials to reach and selectively infect cancer cells when administered by intravenous infusion. PsiOxus will now use the new funding to conduct a Phase I clinical study combining enadenotucirev and an immune-checkpoint inhibitor in patients with metastatic colorectal cancer. With this study, PsiOxus aims to demonstrate that the immune process triggered by enadenotucirev infection of tumour cells, will enable the activity of checkpoint inhibitors in this otherwise immune modulator resistant indication. (Source: press release).



## Selected financing highlights – investors in May, June 2015

The following investors have made investments into European Life Science companies through May, June 2015:


- Finnvera
- Gran Plasa
- High-Tech Gründerfonds (HTGF)
- Imperial Innovations plc (AIM IVO)
- Invesco
- Lifeline Ventures
- Lundbeckfond Ventures
- Mectalent Oy
- Mercia Technologies
- Metsola Ventures
- Novartis Venture Fund
- Redalpine
- SROne (investment arm of GlaxoSmithKline)
- Truffle Capital
- Woodford Investment Management



## Quarterly Biotech Equity Financing Breakdown by Investment Size (Therapeutics & Diagnostics)

The second quarter of 2015 witnessed the highest proportion of investments EUR 30m and above of the past four quarters, at 43% of the total investments in private Biotech companies (Therapeutics and Diagnostics). The smallest investments, those less than EUR 5m, amounted to 29% of the total, well below the previous two quarters where they represented at least half of investments, and matching the levels of Q3 2014.

Strikingly, there were no investments made between EUR 15m and EUR 30m in Q2 2015 for those companies, since the remaining 29% was accounted for by investments between EUR 5m and EUR 15m.



The graph above shows the proportion of financing rounds by most investment size in the therapeutics and diagnostics category per quarter, including only private companies

## May, June 2015 financing rounds summary

Source: Biotechgate – [www.biotechgate.com](http://www.biotechgate.com)

Company Name	Sector	Amount (in Million EUR)	Ownership	Country
Infinitevision Optics	Medical Technology	1.7	Private / independent	France
ABIVAX	Biotechnology - Therapeutics and Diagnostics	58.2	Public	France
Advanced Accelerator Applications SA	Pharma	23.0	Private / independent	France
Galapagos NV	Biotechnology - Therapeutics and Diagnostics	4.4	Public	Belgium
Biotie Therapies Corp.	Biotechnology - Therapeutics and Diagnostics	82.9	Public	Finland
WISE S.r.l.	Medical Technology	3.0	Private / independent	Italy
Endo International plc.	Pharma	1783.8	Public	Ireland
Auspherix Limited (UK)	Biotechnology - Therapeutics and Diagnostics	8.3	Private / independent	United Kingdom
MyoPowers Medical Technologies SA	Medical Technology	4.5	Private / independent	Switzerland
NEOS Surgery, S.L.	Medical Technology	1.9	Private / independent	Spain
PsiOxus Therapeutics	Biotechnology - Therapeutics and Diagnostics	34.6	Private / independent	United Kingdom
Circassia Limited	Biotechnology - Therapeutics and Diagnostics	380.4	Public	United Kingdom
Bavarian Nordic A/S	Biotechnology - Therapeutics and Diagnostics	44.8	Public	Denmark
ZeClinics	Biotechnology / R&D Services	0.1	Private / independent	Spain
Synoste Ltd	Medical Technology	2.2	Private / independent	Finland
Oxford BioMedica	Biotechnology - Therapeutics and Diagnostics	44.8	Public	United Kingdom

## About this summary

The Life Sciences Financing Summary is published on a bi-monthly basis by Venture Valuation and Fit for Health 2.0 and can be downloaded for free either from our newsletter or from the website <http://www.fitforhealth.eu/>

The data used for this summary is taken from Venture Valuation's global Biotech and life science database Biotechgate. Biotechgate is a popular source for life sciences company and licensing deals information. If you are interested in learning more, please do not hesitate to contact us and to apply for a trial.

[Click here to learn more about Biotechgate »](#)

Venture Valuation  
Kasernenstrasse 11  
8004 Zurich  
Switzerland

Phone: +41 (43) 321 86 60  
Web: [www.venturevaluation.com](http://www.venturevaluation.com)  
Email: [info@venturevaluation.com](mailto:info@venturevaluation.com)

Copyright © 2015 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebiotech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at [www.biotechgate.com](http://www.biotechgate.com)